Finegood D T, Hramiak I M, Dupre J
Department of Medicine, University of Alberta, Edmonton, Canada.
J Clin Endocrinol Metab. 1990 Jun;70(6):1538-49. doi: 10.1210/jcem-70-6-1538.
An exogenous insulin administration-modified, frequently sampled iv glucose tolerance test (FSIGT) for application in insulin-dependent diabetic patients (IDDM) to allow for estimation of insulin sensitivity (SI) and glucose effectiveness (SG) with Bergman's minimal model of glucose kinetics was investigated. An insulin infusion protocol (either 4 or 8 mU/min.kg from 20-25 min) was compared to the standard tolbutamide-modified (300 mg at 20 min) FSIGT in normal control subjects. SI and SG were not different for the insulin infusion- and tolbutamide-modified protocols [SI, 2.8 +/- 0.4, 3.6 +/- 0.6, and 2.5 +/- 0.5 X 10(4) min1/(microU/mL), respectively]. SI and SG were quantified in insulin-requiring newly diagnosed IDDM and in noninsulin-requiring IDDM in clinical remission with the exogenous insulin administration protocol. Both SI and SG were reduced in newly diagnosed IDDM compared to normal controls (by 64% and 40%, respectively). SI was normalized in IDDM in clinical remission despite a continued poor insulin secretory response to both glucose and tolbutamide. Although SI was normal in patients in clinical remission, SG remained reduced (by 65%) compared to that in normal controls. In conclusion, our results demonstrate that modification of the FSIGT with the exogenous administration of insulin allows for estimation of insulin sensitivity and glucose effectiveness in IDDM patients. Comparison to the standard protocol in normal subjects suggests that this results in valid measurements of insulin sensitivity and glucose effectiveness. Results of the application of this protocol in IDDM were consistent with previous observations that insulin sensitivity is reduced in poorly controlled IDDM and normalized in well controlled patients. Glucose effectiveness was found to be reduced in all IDDM subjects regardless of the degree of control.
研究了一种外源性胰岛素给药改良的、频繁采样的静脉葡萄糖耐量试验(FSIGT),用于胰岛素依赖型糖尿病患者(IDDM),以便使用伯格曼葡萄糖动力学最小模型来估计胰岛素敏感性(SI)和葡萄糖效能(SG)。在正常对照受试者中,将胰岛素输注方案(20 - 25分钟内为4或8 mU/min·kg)与标准甲苯磺丁脲改良的(20分钟时300 mg)FSIGT进行比较。胰岛素输注方案和甲苯磺丁脲改良方案的SI和SG无差异[SI分别为2.8 +/- 0.4、3.6 +/- 0.6和2.5 +/- 0.5×10(4) min1/(μU/mL)]。使用外源性胰岛素给药方案对新诊断的需胰岛素治疗的IDDM患者和临床缓解期无需胰岛素治疗的IDDM患者的SI和SG进行了量化。与正常对照相比,新诊断的IDDM患者的SI和SG均降低(分别降低了64%和40%)。尽管对葡萄糖和甲苯磺丁脲的胰岛素分泌反应持续不佳,但临床缓解期的IDDM患者的SI恢复正常。尽管临床缓解期患者的SI正常,但与正常对照相比,SG仍降低(降低了65%)。总之,我们的结果表明,外源性胰岛素给药改良的FSIGT能够估计IDDM患者的胰岛素敏感性和葡萄糖效能。与正常受试者的标准方案相比表明,这能有效测量胰岛素敏感性和葡萄糖效能。该方案在IDDM中的应用结果与先前的观察结果一致,即控制不佳的IDDM患者胰岛素敏感性降低,而控制良好的患者胰岛素敏感性恢复正常。发现所有IDDM受试者的葡萄糖效能均降低,与控制程度无关。